Tioguanine

Generic name
Tioguanine
Brand name
ATC Code
L01BB03
Compare …

Tioguanine

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Oncological conditions
  • Oral
    • 1 month up to 18 years
      [2]

      • The dose and dosing frequency of cytostatic agents depend on the condition and are very much subject to new insights. Cytostatic drugs are mostly used in oncology and haematology in combinations. For this reason, please refer to the detailed treatment protocols.

        The following indicative dosages have been stated by the manufacturer: 60-200 mg/m²/day

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Patients with hereditary low activity or absence of activity of thiopurine methyltransferase (TPMT) or with the hereditary mutated NUDT15 gene ((notably occurring in East Asians (10%), Latinos (4%), less in Europeans (0.2%) and not in Africans (0%)) are at increased risk of severe toxicity from tioguanine. Dose reductions are usually required for patients with such mutations, especially those who are homozygous for the NUDT15 variant. Genotypic testing for NUDT15 variants may be considered before initiating therapy.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTIMETABOLITES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Purine analogues
L01BB02
Pyrimidine analogues
L01BC01

References

  1. Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
  2. GlaxoSmithKline BV, SPC Lanvis (RVG 07070), www.cbg-meb.nl, Geraadpleegd 09 juli 2010, http://db.cbg-meb.nl/IB-teksten/h07070.pdf

Changes

Therapeutic Drug Monitoring


Overdose